← Leaderboards
Terry D Hinds
University Of Toledo Health Sci Campus
$4,061,373
Attributed
$5,119,392
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,119,392 · 5
By mechanism
R01$4,272,041 · 3
K01$778,999 · 1
F31$68,352 · 1
Top collaborators
- Cassandra D Gipson-Reichardt3 shared
- David E Stec1 shared
Most similar at University Of Toledo Health Sci Campus
Same institution · by research overlap
- Edwin Ramon Sanchez$3,707,667
Others in their field
Top investigators on “Affect”
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$287,585,588
- Chanza Baytop · Westat, Inc.$271,217,917
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$209,385,844
- David Heimbrook · Leidos Biomedical Research, Inc.$168,138,264
- Daniel R Kuritzkes · Brigham And Women'S Hospital$151,687,019
Research focus
AffectSignal TransductionFatty Acid Glycerol EstersCardiovascular DiseasesLigandsObesityEventResistancePlasmaMolecularAdipocytesOverweightDiabetes MellitusAdipose TissueLipidsGlucoseHormonesSerumAdultInsulinInsulin ResistanceCardiovascular SystemMediatingPpar Alpha
Grant awards (19)
Novel liver-mediated mechanisms in hypertension and cardiac dysfunction$604,818
R01 · FY2025 · HL
Neurobehavioral mechanisms underlying xylazine and fentanyl co-use and withdrawal$496,587
R01 · FY2025 · DA
Neurobehavioral mechanisms underlying xylazine and fentanyl co-use and withdrawal$502,057
R01 · FY2024 · DA
Novel Liver Signaling Pathways Controlling Adiposity$397,165
R01 · FY2024 · DK · contact PI
Novel Liver Signaling Pathways Controlling Adiposity$28,649
R01 · FY2024 · DK · contact PI
Neurobehavioral mechanisms underlying xylazine and fentanyl co-use and withdrawal$512,576
R01 · FY2023 · DA
Novel Liver Signaling Pathways Controlling Adiposity$413,714
R01 · FY2023 · DK · contact PI
Novel Liver Signaling Pathways Controlling Adiposity$69,023
R01 · FY2023 · DK · contact PI
Novel Liver Signaling Pathways Controlling Adiposity$410,137
R01 · FY2022 · DK · contact PI
Novel Liver Signaling Pathways Controlling Adiposity$408,414
R01 · FY2021 · DK · contact PI
Novel Liver Signaling Pathways Controlling Adiposity$420,511
R01 · FY2020 · DK · contact PI
Novel Liver Signaling Pathways Controlling Adiposity$8,390
R01 · FY2020 · DK · contact PI
Antioxidant-PPARalpha interaction and hypertension$163,213
K01 · FY2019 · HL · contact PI
Antioxidant-PPARalpha interaction and hypertension$163,213
K01 · FY2018 · HL · contact PI
Antioxidant-PPARalpha interaction and hypertension$163,213
K01 · FY2017 · HL · contact PI
Antioxidant-PPARalpha interaction and hypertension$154,171
K01 · FY2016 · HL · contact PI
Antioxidant-PPARalpha interaction and hypertension$135,189
K01 · FY2015 · HL · contact PI
Fatty acid Control Obesity and the Metabolic Syndrome via TPR proteins$34,380
F31 · FY2010 · DK · contact PI
Fatty acid Control Obesity and the Metabolic Syndrome via TPR proteins$33,972
F31 · FY2009 · DK · contact PI